Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Subscribe To Our Newsletter & Stay Updated
